ClinicalTrials.gov
ClinicalTrials.gov Menu

Neoadjuvant TDM1 With Lapatinib and Abraxane Compared With Trastuzumab Plus Pertuzumab With Paclitaxel (TEAL)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02073487
Recruitment Status : Active, not recruiting
First Posted : February 27, 2014
Last Update Posted : July 25, 2018
Sponsor:
Collaborators:
Celgene Corporation
Novartis
The Methodist Hospital System
Information provided by (Responsible Party):
Jenny C. Chang, MD, The Methodist Hospital System

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Active, not recruiting
  Estimated Primary Completion Date : January 2019
  Estimated Study Completion Date : June 2019